Table 1.
Baseline and follow-up characteristics of HIV-infected women in the MTCT-Plus program (N = 290).
| At initiation of treatment | |
|---|---|
| Period at HAART initiation | |
| Pregnant/non pregnant, n (%) | 125/165 (43/57) |
| Exposed women to PMTCT | |
| Exposed/no exposed, n (%) | 153/137 (53/47) |
| Age, years, median [IQR] | 29 [26-33] |
| >29 years | 137 (47) |
| Body mass index, Kg/m2 [IQR] | 22.3 [20.1-25.3] |
| >18.5 * | 250 (86) |
| WHO clinical stage, n (%) | |
| 1 | 33 (11) |
| 2 | 127 (44) |
| 3 | 117 (40) |
| 4 | 13 (5) |
| CD4 counts, cells/mm3 [IQR] | 186 [124-266] |
| >250 | 88 (30) |
| Co-trimoxazole, n (%) | 287 (99) |
| Haemoglobin level, g/l, median [IQR] | 9.8 [9-11] |
| ≤9.8 | 150 (52) |
| Neutrophil count, mm3, median [IQR] | 2639 2639 [1911-3712] |
| <1500 | 28 (10) |
| HAART regimen, n (%) | |
| ZDV/3TC/NVP | 265 (91) |
| d4T/3TC/NVP | 25 (9) |
| Alanine aminotransferase, UI, median [IQR] | 15 [11-24] |
| <31 IU/L* | 240 (83) |
| Aspartate aminotransférase, UI, median [IQR] | 24 [19-31] |
| <32 IU/L* | 235 (81) |
| Follow-up | |
| Cumulative, person-months | 6388 |
| Per patient, months, median [IQR] | 25 [14-30] |
| Status on study termination | |
| Dead, n (%) | 16 (6) |
| Lost to follow-up, n (%) | 7 (2) |
| Alive, n (%) | 267 (92) |
HAART: Highly active antiretroviral therapy; PMTCT: prevention to mother-to-child transmission; WHO: World Health Organization; IQR: interquartile range; ZDV: zidovudine; 3TC: lamivudine; NVP: nevirapine; d4T: stavudine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IU: International unity;
* upper limit of normal